Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray

Fertility and Sterility

Volumn 67, Issue 3, 1997, Pages 469-473

  Fujimoto, Victor Y ^a,b   Monroe, Scott E ^a   Nelson, Linda R ^a,c   Downey, Deborah ^a   Jaffe, Robert B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

GnRH antagonist; intranasal administration; luteinizing hormone suppression

Indexed keywords

ESTRADIOL; GANIRELIX; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; ENDOMETRIOSIS; FEMALE; FOLLICULAR PHASE; GONADOTROPIN RELEASE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INTRANASAL DRUG ADMINISTRATION; LACRIMATION; LUTEINIZING HORMONE RELEASE; NORMAL HUMAN; NOSE CONGESTION; NOSE IRRITATION; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; UTERUS MYOMA;

EID: 0031037234     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)80071-4     Document Type: Article

References (21)

1. Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone nafarelin. Fertil Steril 1985;44:583-8.
2. Henzl M, Corson S, Moghissi K, Buttram V, Berquist C, Jacobsen J. Administration of nasal nafarelin as compared with danazol for endometriosis: a multi-center double-blind comparative trial. N Engl J Med 1988;318:485-9.
3. Andreyko J, Blumenfeld Z, Marshall L, Monroe S, Hricak H, Jaffe R. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988;158:903-10.
4. Andreyko J, Monroe S, Jaffe R. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J Clin Endocrinol Metab 1986;63:854-9.
5. Hazum E, Keinan D. Gonadotropin releasing hormone activation is mediated by dimerization of occupied receptors. Biochem Biophys Res Commun 1985;133:449-56.
6. Gregory H, Taylor C, Hopkins C. Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors. Nature 1982;300:269-71.
7. Cetel N, Rivier J, Vale W, Yen S. The dynamics of gonadotropin inhibition in women Induced by an antagonistic analog of gonadotropin-releasing hormone. J Clin Endocrinol Metab 1983;57:62-5.
8. Davis M, Veldhuis J, Rogol A, Dufau M, Catt K. Sustained inhibitory actions of a potent antagonist of gonadotropin-releasing hormone in postmenopausal women. J Clin Endocrinol Metab 1987;64:1268-74.
9. Mortola JF, Sathanandan M, Pavlou S, Dahl K, Hsueh A, Rivier J, et al. Suppression of bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone levels by a potent gonadotropin-releasing hormone antagonist: pharmacodynamic studies. Fertil Steril 1989;51:957-63.
10. Hahn D, McGune J, Vale W, Rivier J. Reproductive/endocrine and anaphylactoid properties of an LHRH antagonist, ORL 18260 [Ac-D-Nal(2),4FdPhe2,D-Trp-3,n-Arg3]GnRH. Life Sci 1985;37:506-14.
11. Mais V, Kazer R, Cetel N, Rivier J, Vale W, Yen S. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a GnRH antagonist probe. J Clin Endocrinol Metab 1986;62:1250-4.
12. Andreyko J, Monroe S, Marshall L, Fluker M, Nerenberg C, Jaffe R. Concordant suppression of serum immunoreactive LH, FSH, alpha subunit, bioactive LH and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (Detirelix). J Clin Endocrinol Metab 1992;74:399-405.
13. Pavlou S, Wakefield G, Island D, Hoffman P, LePage M, Chan R, et al. Suppression of pituitary-gonadal function by a potent new luteinizing hormone antagonist in normal men. J Clin Endocrinol Metab 1987;64:931-6.
14. Rabinovici J, Rothman P, Monroe S, Nerenberg C, Jaffe R. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J Clin Endocrinol Metab 1992;75:1220-5.
15. Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary-gonadal function by a potent, new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 1995;63:963-9.
16. Nestor JJ, Tahilramani R, Ho T, Goodpasture J, Vickery B, Ferrandon P. Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35:3942-8.
17. Nerenberg C, LaFargue J, Gee C, Chu F, Wolfe L, Chan R, et al. Radioimmunoassay of ganirelix in plasma or serum. J Immunoassay 1993;14:191-207.
18. Marshall L, Fluker M, Jaffe R, Monroe S. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (Detirelix). J Clin Endocrinol Metab 1991;72:927-33.
19. Fluker M, Marshall L, Monroe S, Jaffe R. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle. J Clin Endocrinol Metab 1991;72:912-9.
20. Hall J, Brodie T, Badger T, Rivier J, Vale W, Conn M, et al. Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist. J Clin Endocrinol Metab 1988;67:524-31.
21. Behre H, Klein B, Steinmeyer E, McGregor G, Voigt K, Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 1992;75:393-8.